At his confirmation hearing last month to lead the Food and Drug Administration, Robert Califf was pressed by U.S. senators for his views on the opioid crisis, on tobacco and e-cigarette regulation, and on his relationship with pharmaceutical and tech companies.
Califf came prepared and, by all accounts, sailed through.
But the hearing did little to address a fundamental question: Who is Robert Califf, and what can we expect him to do?
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect